FDA Approves First BAFF/APRIL Blocker to Fight Kidney Disease IgA Nephropathy
Atacicept cuts proteinuria by 42% in a phase III trial, offering a novel immune-targeting approach for a condition that can lead to kidney failure.
Summary
The FDA has granted accelerated approval to atacicept (Trutakna), a first-in-class injectable drug for IgA nephropathy — the most common primary kidney glomerular disease. The drug works by blocking two immune signaling proteins, BAFF and APRIL, which drive the abnormal IgA antibody buildup that damages kidney filters. In a phase III placebo-controlled trial called ORIGIN 3, atacicept reduced proteinuria by 42% at 36 weeks and cut levels of a key disease marker by 68%. About half of IgA nephropathy patients progress to kidney failure or death within 10 to 20 years of diagnosis. While the results are promising, long-term data confirming whether the drug actually slows kidney function decline are still pending and expected later this year.
Detailed Summary
IgA nephropathy is the world's most common primary glomerular kidney disease, affecting an estimated 2.5 per 100,000 adults annually. Though often diagnosed in young adulthood, roughly half of patients progress to kidney failure or death within 10 to 20 years. Until recently, treatment options were limited, making new therapeutic approvals particularly meaningful for long-term health and survival.
The FDA has now granted accelerated approval to atacicept (Trutakna), developed by Vera Therapeutics, as the first drug to simultaneously block both BAFF and APRIL — two immunoregulatory cytokines central to the disease's pathophysiology. By inhibiting these signals, atacicept suppresses the overactive B-cell activity responsible for producing the abnormal IgA antibodies that accumulate in and damage the kidneys' glomeruli.
Approval was supported by data from the ORIGIN 3 phase III placebo-controlled trial. Participants receiving atacicept via once-weekly self-injection achieved a 42% reduction in proteinuria — a key marker of kidney damage — at week 36, with high statistical significance. They also showed a 68% reduction in galactose-deficient IgA1, a secondary biomarker directly tied to disease mechanism.
Despite these results, the approval is accelerated, meaning definitive long-term kidney function outcomes have not yet been confirmed. As a regulatory condition, Vera Therapeutics must provide data from the ongoing ORIGIN 3 trial demonstrating that atacicept genuinely slows kidney function decline over time. Those results are anticipated later in 2026.
Safety data indicate a meaningful infection risk: 32% of treated participants experienced infections, most commonly upper respiratory tract infections. Injection site reactions were also common. The drug carries warnings around immunosuppression and is contraindicated in patients with prior serious hypersensitivity. For clinicians and patients managing IgA nephropathy, atacicept adds a mechanistically novel option to an increasingly active therapeutic landscape.
Key Findings
- Atacicept reduced proteinuria by 42% at 36 weeks versus placebo in a phase III trial.
- The drug cut galactose-deficient IgA1 levels by 68%, targeting the root disease mechanism.
- Atacicept is the first approved therapy to block both BAFF and APRIL cytokines simultaneously.
- About half of IgA nephropathy patients develop kidney failure or die within 10–20 years of diagnosis.
- Long-term kidney function data are still pending; approval is accelerated, not full FDA authorization.
Methodology
This is a news report from MedPage Today summarizing FDA approval and associated phase III clinical trial data (ORIGIN 3). The source is a credible medical news outlet with direct reference to trial endpoints and regulatory context. No primary study paper is linked; evidence basis is the ORIGIN 3 placebo-controlled phase III trial results as cited in a company press release.
Study Limitations
Accelerated approval means long-term kidney function benefits remain unconfirmed; confirmatory data are expected but not yet published. The article relies partly on company press release data rather than a peer-reviewed publication. Proteinuria reduction is a surrogate endpoint, not a direct measure of kidney survival.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: